Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Vorinostat does not improve ou...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Bibliographic Details
Main Authors: Craddock, C, Houlton, A, Ferguson, P, Raghavan, M, Fox, S, Dudley, L, Quek, L, Cavenagh, J, Dennis, M, McMullin, M, Pillai, S, Kelly, R, Siddique, S, Wheatley, K, Vyas, P
Format: Conference item
Published: American Society of Hematology 2016
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
    by: Craddock, C, et al.
    Published: (2017)
  • Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
    by: Craddock, C, et al.
    Published: (2017)
  • Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
    by: Craddock, C, et al.
    Published: (2013)
  • Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
    by: Craddock, C, et al.
    Published: (2013)
  • INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
    by: Goodyear, O, et al.
    Published: (2010)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs